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IMPORTANCE There is an urgent need to improve lung cancer risk assessment because
current screening criteria miss a large proportion of cases.
OBJECTIVE To investigate whether a lung cancer risk prediction model based on a panel of
selected circulating protein biomarkers can outperform a traditional risk prediction model
and current US screening criteria.
DESIGN, SETTING, AND PARTICIPANTS Prediagnostic samples from 108 ever-smoking patients
with lung cancer diagnosed within 1 year after blood collection and samples from 216
smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were
used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125],
carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor
form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated
blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer
diagnosed within 1 year after blood collection and 90 matched controls from 2 large
European population-based cohorts, the European Prospective Investigation into Cancer and
Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS).
MAIN OUTCOMES AND MEASURES Model validity in discriminating between future lung cancer
cases and controls. Discrimination estimates were weighted to reflect the background
populations of EPIC and NSHDS validation studies (area under the receiver-operating
characteristics curve [AUC], sensitivity, and specificity).
RESULTS In the validation study of 63 ever-smoking patients with lung cancer and 90
matched controls (mean [SD] age, 57.7 [8.7] years; 68.6% men) from EPIC and NSHDS, an
integrated risk prediction model that combined smoking exposure with the biomarker score
yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a
model based on smoking exposure alone (P = .003 for difference in AUC). At an overall
specificity of 0.83, based on the US Preventive Services Task Force screening criteria, the
sensitivity of the integrated risk prediction (biomarker) model was 0.63 compared with 0.43
for the smoking model. Conversely, at an overall sensitivity of 0.42, based on the US
Preventive Services Task Force screening criteria, the integrated risk prediction model yielded
a specificity of 0.95 compared with 0.86 for the smoking model.
CONCLUSIONS AND RELEVANCE This study provided a proof of principle in showing that a
panel of circulating protein biomarkers may improve lung cancer risk assessment and may be
used to define eligibility for computed tomography screening.
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T he National Lung Screening Trial (NLST) findingssuggested that screening with low-dose computed to-mography (LDCT) can reduce lung cancer mortality.1 As
a result, the US Preventive Services Task Force (USPSTF) rec-
ommends LDCT screening for lung cancer among individuals
aged 55 to 80 years who have smoked 30 pack-years with up
to 15 years since quitting smoking.1,2 However, LDCT screen-
ing results in a large number of indeterminate nodules,1 and
less than 50% of incident lung cancer cases are among indi-
viduals who are eligible for screening.3 Biomarkers may
improve lung cancer risk assessment over and beyond tradi-
tional smoking-based risk models and improve current screen-
ing eligibility criteria.4,5
Previous studies have shown that the precursor form of
surfactant protein B (Pro-SFTPB) is predictive of lung cancer
risk.5,6 Other markers that have been shown to be useful for
the workup and diagnosis of lung cancer include cancer anti-
gen 125 (CA125), cytokeratin-19 fragment (CYFRA 21-1), carci-
noembryonic antigen (CEA), and human epididymis protein
4 (HE4).7-12 However, there are limited data regarding the per-
formance of these markers in discriminating between future
lung cancer cases and controls.
This study aimed to assess the potential of these 5 pro-
tein biomarkers to inform about lung cancer risk when tested
blindly using prediagnostic samples.
Methods
A full account of the methods is provided in the eMethods
in the Supplement. In brief, samples obtained from ever-
smoking patients with lung cancer (cases) diagnosed within 1
year after blood collection (n = 108) and smoking-matched con-
trols (n = 216) from the US Carotene and Retinol Efficacy Trial
(CARET) cohort were used to develop a biomarker score based
on circulating measures of Pro-SFTPB, CA125, CEA, HE4, and
CYFRA 21-1 using logistic regression. All study participants gave
written informed consent to participate in the study, and the
research was approved by the institutional review boards of
all of the participating institutions.
The extent to which the biomarker score improved dis-
crimination of incident lung cancer cases and controls was vali-
dated externally using ever-smoking patients with lung can-
cer (cases) diagnosed within 1 year after blood collection
(n = 63) and matched controls (n = 90) from the European Pro-
spective Investigation into Cancer and Nutrition (EPIC) study
and the Northern Sweden Health and Disease Study (NSHDS)
(eFigure 1 in the Supplement). Absolute 1-year risks of lung
cancer were estimated for each study participant in the vali-
dation study by modeling the cumulative hazards of lung
cancer using flexible parametric survival models.13 Two
models were evaluated: a traditional smoking history–based
risk model and an integrated risk prediction model that com-
bined the smoking model and the biomarker score. Model
discrimination was assessed by receiver operating character-
istic (ROC) analysis using the predicted 1-year lung cancer
risks as scoring rule. Discrimination estimates included area
under the ROC curve (AUC), sensitivity, and specificity,
which were weighted to reflect the background populations.
In the context of using the 1-year absolute risk of lung cancer
to define screening eligibility, the sensitivity provides an
estimate of the fraction of future lung cancer cases that
would be eligible for screening at a certain absolute risk
threshold. Conversely, the specificity provides an estimate
of the fraction of individuals from the background popula-
tion who remain healthy and would not be eligible for
screening. A sensitivity of 1.00 (or 100%) would indicate that
all lung cancer cases are eligible for screening and a specific-
ity of 1.00 (100%) would indicate that all individuals who
remain healthy are not eligible for screening (ie, that there
are no false-positive controls). Statistical significance was
assumed at a 2-sided P < .05.
Results
Details of the biomarker score and discrimination estimates
in the CARET training study are available in eTables 1 and 2
and eFigures 2 and 3 in the Supplement. In the validation
study of 63 ever-smoking patients with lung cancer and 90
matched controls (mean [SD] age, 57.7 [8.7] years; 68.6%
men) from EPIC and NSHDS, the predicted risk of receiving
a diagnosis of lung cancer within 1 year for a 60-year-old
man with 30 pack-years of smoking history was estimated
at 0.37% using the smoking model (Figure 1). In compari-
son, using the integrated risk prediction model, we esti-
mated 1-year risks at 0.07% and 1.56% for the same man
assuming a biomarker score equal to the average of the first
and fourth quartile, respectively. The 1-year lung cancer risk
estimates for each study participant in the validation study
according to the smoking and integrated risk prediction
models are shown in Figure 2. In comparison with the
smoking model, the median 1-year risk estimates from the
integrated risk prediction model increased for cases from
0.27% (interquartile range [IQR], 0.14%-0.50%) to 0.45%
(IQR, 0.18%-1.5%) and decreased for controls from 0.12%
(IQR, 0.05%-0.21%) to 0.04% (IQR, 0.015%-0.17%).
In the validation study, the population-weighted AUC
was 0.73 (95% CI, 0.64-0.82) for the smoking model and
0.83 (95% CI, 0.76-0.90) for the integrated risk prediction
Key Points
Question Can a risk prediction model based on circulating protein
biomarkers improve on a traditional risk prediction model for lung
cancer and the current US screening criteria?
Findings In a validation study of 63 ever-smoking patients with
lung cancer and 90 matched controls, a biomarker-based risk
prediction model consisting of 4 protein markers that was
developed in a cohort of US individuals at high risk of lung cancer
outperformed a model based on smoking history alone when
blindly validated using prediagnostic samples from 2 European
cohorts.
Meaning Biomarker-based risk profiling has the potential to
improve eligibility criteria for lung cancer screening.
Research Brief Report Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins
2/6 JAMA Oncology October 2018 Volume 4, Number 10 (Reprinted) jamaoncology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ on 11/11/2020
model (P = .003 for difference in AUC) (Figure 3A). The
AUCs were consistently higher for the integrated model
than for the smoking model across relevant strata (eTable 3
in the Supplement). At an overall specificity of 0.83 based
on the USPSTF screening criteria, the integrated risk predic-
tion model yielded a sensitivity of 0.63 (95% CI, 0.49-0.76)
compared with 0.43 (95% CI, 0.23-0.65) for the smoking
model. Similarly, at an overall sensitivity of 0.42 (USPSTF),
the integrated risk prediction model yielded a specificity of
0.95 (95% CI, 0.85-0.99) compared with 0.86 (95% CI, 0.72-
0.94) for the smoking model. The improvement in AUC for
the integrated risk prediction model (AUC, 0.80; 95% CI,
0.75-0.85) over the smoking model (AUC, 0.73; 95% CI,
0.68-0.79) was more modest when cases diagnosed up to 2
years after blood draw were considered (eFigure 4 in the
Supplement). A full account of all conducted analyses is
provided in the eResults; eTables 1, 2, and 4 to 10; and
eFigures 6 to 10 of the Supplement.
Figure 2. Predicted Probabilities of Lung Cancer Within 1 Year Based on the Smoking and Integrated Risk
Prediction Models in the Validation Study (European Prospective Investigation Into Cancer and Nutrition
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The validation samples consist of
EPIC and NSHDS ever-smoking
participants who received a diagnosis
of lung cancer within 1 year after
blood collection. For the controls, the
size of the points is proportional to
the number of eligible participants
represented (corresponding to the
inverse of the sampling probability).
The right panel represents a
magnified excerpt of the full figure.
Figure 1. Predicted Probability of Lung Cancer Within 1 Year for a Male From the Northern Sweden Health and Disease Study (NSHDS)






















































Integrated risk prediction modelB
Q1 Q2 Q3 Q4Former smokers (quit 15 y ago)
Former smokers (quit 5 y ago)
Current smokers (15 pack−years)
Current smokers (30 pack−years)
A, Predicted probability of lung cancer according to the smoking risk prediction
model based on age in years and smoking history. The rug plot shows the
observed distribution of age in the validation study (European Prospective
Investigation into Cancer and Nutrition [EPIC] and NSHDS, ever smokers).
B, Predicted probability of lung cancer according to the integrated risk
prediction model based on the biomarker score and the smoking history. The
rug plot shows the observed distribution of the biomarker score in the
validation study (EPIC and NSHDS, ever smokers). The vertical lines correspond
to the quartiles threshold for biomarker score among controls (Q1, Q2, Q3,
and Q4).
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Discussion
This is, to our knowledge, the first study in which a blood-
based biomarker score was developed using one cohort and
externally validated using prediagnostic samples from other
independent cohorts. We observed a notable improvement in
discrimination between future lung cancer cases and con-
trols over a traditional smoking-based risk prediction model
by incorporating information from a biomarker score consist-
ing of 4 circulating proteins.
In our validation study, 26 of the 62 incident lung cancer
cases (42%, corresponding to a sensitivity of 0.42) would
have qualified for LDCT screening according to USPSTF cri-
teria (USPSTF eligibility criteria could not be assessed for
1 case). Using the biomarker score together with smoking
information, we estimated that 40 of 63 cases (63%, corre-
sponding to a sensitivity of 0.63) could be identified with-
out increasing the number of eligible controls (ie, without
decreasing the specificity). The data further suggested that
the biomarker score could alternatively be used to reduce
screening of individuals not destined to develop lung cancer
(false positives) from 15 of 90 controls (17%) to 4 of 90 con-
trols (5%) without affecting the uptake of future lung cancer
cases (sensitivity). These improvements in sensitivity and
specificity were consistently observed across each evalu-
ated stratum. Our findings also indicated that the improve-
ment in discrimination afforded by the biomarker score is
more modest beyond the initial year after blood draw,
which suggests that an annual biomarker test may be neces-
sary in a screening program.
Strengths and Limitations
Naive discrimination estimates, as typically provided in a
matched, nested, case-control setting, are inherently biased.
An important strength of our study was the use of absolute risks
and population-based discrimination estimates, which were
necessary to estimate the number of individuals who would
be selected for screening using the biomarker-based eligibil-
ity criterion in the overall background cohorts, beyond our spe-
cific case-control study.
A limitation of our study was that 3 variables that were
originally included in a validated risk prediction model (the
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
model from 2012 [PLCOM2012]) were not available in our vali-
dation studies.14 However, with use of the original PLCO data,
the exclusion of these variables from the PLCOM2012 model only
nominally decreased the model’s performance, which sug-
gests that our risk prediction model represented a valid com-
parison for the biomarkers score (eMethods and eFigure 5 in
the Supplement).14
Although this study provided a proof of principle of the
potential of using biomarkers in lung cancer risk assessment
to define screening eligibility, validating and calibrating the
integrated risk prediction model using larger sample size
with prediagnostic samples is clearly needed before such a
risk prediction tool can be used in practice. A larger sample
size will also allow stratified analysis to evaluate the perfor-
mance of the biomarker panel in predicting lung cancer
cases associated with different characteristics, such as stage
at diagnosis and histologic subtype. Furthermore, our study
was limited to a select panel of circulating proteins, and
we note that other types of biomarkers may also be
Figure 3. Receiver Operating Characteristic (ROC) Curve Analysis in the Validation Study (European Prospective Investigation Into Cancer















Smoking + biomarkers: AUC (95% CI),
0.83 (0.76−0.90)
























Integrated risk prediction modelB
USPSTF
A, ROC curve analysis in the validation study (EPIC and NSHDS ever-smoker participants who received a diagnosis of lung cancer within 1 year after blood collection)
for 2 risk prediction models: a model that used smoking variables only (smoking) and an integrated model with the smoking variables and the biomarker score
combined (smoking + biomarkers). AUC indicates area under the curve; USPSTF, US Preventive Services Task Force. The horizontal dashed line indicates sensitivity
and the vertical dashed line, specificity. B, Sensitivity and specificity in relation to the probability of lung cancer within 1 year predicted by the integrated model.
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informative.4,5 We also note that the population that would
most benefit from a biomarker test before undergoing
LDCT screening remains to be defined. A thorough cost-
effectiveness assessment based on a large study sample is
warranted to determine the threshold in absolute risk of
developing lung cancer during a specific period, above
which the benefits of screening outweigh the harms.15
Conclusions
This study provides a proof of principle in demonstrating that
circulating biomarkers have the potential to inform lung can-
cer risk assessment and substantially improve on current
criteria for LDCT screening.
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